2018
Impact of carboplatin hypersensitivity and desensitization on patients with recurrent ovarian cancer
Altwerger G, Florsheim EB, Menderes G, Black J, Schwab C, Gressel GM, Nelson WK, Carusillo N, Passante T, Huang G, Litkouhi B, Azodi M, Silasi DA, Santin A, Schwartz PE, Ratner ES. Impact of carboplatin hypersensitivity and desensitization on patients with recurrent ovarian cancer. Journal Of Cancer Research And Clinical Oncology 2018, 144: 2449-2456. PMID: 30255380, DOI: 10.1007/s00432-018-2753-y.Peer-Reviewed Original ResearchConceptsCarboplatin hypersensitivityCarboplatin desensitizationHypersensitive patientsOverall survivalRisk factorsOvarian cancerTwo-sided Fisher exactAdvanced stage ovarian cancerInfusion of carboplatinRecurrent ovarian cancerIndependent risk factorLonger overall survivalStage ovarian cancerOvarian cancer patientsLong-term treatmentNew risk factorsHigher likelihoodTwo-sided p valueT-testStudent's t-testDesignRetrospective studyGermline BRCA1/2Improved OSLonger OSDesensitization protocol
2011
Phase II trial of adjuvant pelvic radiation “sandwiched” between combination paclitaxel and carboplatin in women with uterine papillary serous carcinoma
Einstein MH, Frimer M, Kuo D, Reimers LL, Mehta K, Mutyala S, Huang GS, Hou JY, Goldberg GL. Phase II trial of adjuvant pelvic radiation “sandwiched” between combination paclitaxel and carboplatin in women with uterine papillary serous carcinoma. Gynecologic Oncology 2011, 124: 21-25. PMID: 22035806, PMCID: PMC3681611, DOI: 10.1016/j.ygyno.2011.10.007.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBrachytherapyCarboplatinCarcinoma, PapillaryCystadenocarcinoma, SerousDose Fractionation, RadiationDrug Administration ScheduleFemaleHumansMiddle AgedNeoplasm StagingPaclitaxelRadiotherapy, AdjuvantUterine NeoplasmsConceptsAdjuvant pelvic radiationCycles of paclitaxelCycles of chemotherapyRadiation therapyPelvic radiationCarboplatin chemotherapyUterine papillary serous carcinomaExtra-uterine diseaseModality adjuvant therapyNon-hematologic toxicitiesPrescribed radiation therapyVisible residual diseasePhase II trialKaplan-Meier methodPapillary serous carcinomaStage 3Stage 1Combination paclitaxelOverall PFSAdjuvant therapyChemotherapy cyclesII trialMedian ageResidual diseaseSerous carcinoma